SS Innovations International (NASDAQ:SSII) CEO Sells $99,999.00 in Stock

SS Innovations International, Inc. (NASDAQ:SSII) CEO Srivastava Sudhir sold 33,333 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $3.00, for a total value of $99,999.00. Following the sale, the chief executive officer owned 108,520,928 shares of the company’s stock, valued at $325,562,784. This trade represents a 0.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

SS Innovations International Price Performance

Shares of SSII stock opened at $3.31 on Friday. The stock’s 50-day moving average is $3.63 and its 200 day moving average is $4.05. SS Innovations International, Inc. has a 1-year low of $3.11 and a 1-year high of $10.00. The company has a market cap of $663.26 million, a P/E ratio of -55.17 and a beta of -1.94.

SS Innovations International (NASDAQ:SSII) last announced its earnings results on Thursday, August 13th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $13.94 million during the quarter. SS Innovations International had a negative return on equity of 26.77% and a negative net margin of 23.73%.

SS Innovations International News Summary

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: SS Innovations announced that its robotic technology is being used to bring robotic cardiac surgery to Sri Lanka, supporting the company’s strategy of expanding access to its SSi Mantra system in international markets. SS Innovations Brings Robotic Cardiac Surgery to Sri Lanka
• Positive Sentiment: The company reported 79% growth in SSi Mantra procedures and cited expanding installations, utilization and global reach. Higher procedure volumes could improve recurring revenue potential and validate demand for its robotic-surgery platform. SS Innovations Reports 79% Growth in SSi Mantra Procedures
• Positive Sentiment: Additional milestones include progress in pediatric robotic surgery and telesurgery, which could broaden SSII’s addressable market and strengthen its technology profile if commercial adoption follows. SS Innovations Provides Update on Continuing Progress and Milestones
• Neutral Sentiment: Reported short interest was zero shares, meaning there is no meaningful short position available to create either short-covering support or additional short-selling pressure. The company’s shares remain near their 52-week low and below both the 50-day and 200-day moving averages.
• Negative Sentiment: CEO Sudhir Srivastava sold 33,333 shares for approximately $100,000. The sale reduced his holdings by only 0.03%, but insider selling can modestly weaken investor confidence. SEC Insider Ownership Filing
• Negative Sentiment: SSII continues to report losses, including a recent quarterly loss of $0.01 per share, negative net margin and negative return on equity. Analyst coverage is also broadly bearish, with an average rating of “Sell,” despite a $7 price target from one analyst.

Wall Street Analysts Forecast Growth

SSII has been the subject of several recent analyst reports. Loop Capital set a $7.00 price objective on shares of SS Innovations International in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SS Innovations International in a report on Friday, July 17th. Finally, Wall Street Zen raised SS Innovations International from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, SS Innovations International has a consensus rating of “Sell” and a consensus price target of $7.00.

Institutional Trading of SS Innovations International

Several large investors have recently bought and sold shares of SSII. PNC Financial Services Group Inc. acquired a new stake in shares of SS Innovations International during the third quarter worth $56,000. Envestnet Asset Management Inc. acquired a new position in shares of SS Innovations International in the 3rd quarter valued at $71,000. Jane Street Group LLC acquired a new position in shares of SS Innovations International in the 4th quarter valued at $63,000. IFC & Insurance Marketing Inc. acquired a new stake in SS Innovations International during the 4th quarter worth about $64,000. Finally, Goldman Sachs Group Inc. acquired a new stake in SS Innovations International during the 4th quarter worth about $68,000.

SS Innovations International Company Profile

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.